Program
camizestrant
Also written as “AZD9833”, “Camizestrant” and “AZD9833 with palbociclib”.
Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Lymphoma, Follicular, led by AstraZeneca.
Drug pageAZD9833: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 189 open or running | phase 3since Dec 23, 2020 | Jul 6, 2018 | Apr 20, 2027phase 3 · NCT05774951 |
Also a collaborator on its studies: ICON, Quotient Sciences and Parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 6, 2018.
- Sep 8, 2020Phase 2 study in Breast NeoplasmsNCT04588298 · 135 enrolled · Georgia, Mexico, United Kingdom
- Sep 8, 2020Phase 1 study in Breast NeoplasmsNCT04546347 · 32 enrolled · United Kingdom
- Dec 23, 2020Phase 3 study in Neoplasm MetastasisNCT04711252 · 1,371 enrolled · United States, Austria, Belgium and more
- Mar 24, 2021Phase 1 study in Breast NeoplasmsNCT04818632 · 28 enrolled · China
- Jun 30, 2021Phase 3 study in Neoplasm MetastasisNCT04964934 · 315 enrolled · United States, Australia, Austria and more
- Jul 28, 2021Named camizestrantINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AZD9833
- May 4, 20222 phase 1 studies in Breast NeoplasmsNCT05364255, NCT05438303
- Sep 20, 2022Phase 1 study in Breast NeoplasmsNCT05551897 · 14 enrolled · United Kingdom
- Jan 25, 2023Phase 1 study in Lymphoma, FollicularNCT05790304 · 22 enrolled · United States, Bulgaria, Slovakia
- Feb 16, 2023Phase 3 study in Breast NeoplasmsNCT05774951 · 4,300 planned · United States, Argentina, Australia and more
- May 17, 2023Phase 3 study in Breast NeoplasmsNCT05952557 · 5,511 enrolled · United States, Argentina, Australia and more
- Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
- Aug 7, 2024Phase 1 study in Breast NeoplasmsNCT06547164 · 40 enrolled · United Kingdom
- Feb 16, 2026Phase 2 study in Advanced Breast CancerNCT07427394 · 24 planned · United States, United Kingdom
- May 12, 2026Phase 3 study in Neoplasm MetastasisNCT07647328 · 150 planned · United States, France, Germany and more
Ahead
- Apr 20, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05774951
- Dec 28, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07427394
- Feb 28, 2029Primary completion: phase 3 study in Neoplasm MetastasisNCT07647328
- Dec 18, 2029Primary completion: phase 3 study in Advanced Breast CancerNCT06380751
TargetBeta
“An orally available selective estrogen receptor degrader (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07647328Neoplasm Metastasis · United States, France, Germany and more | 3 | Recruiting | Feb 28, 2029 | 150 |
| NCT07427394Advanced Breast Cancer · United States, United Kingdom | 2 | Recruiting | Dec 28, 2027 | 24 |
| NCT06547164Breast Neoplasms · United Kingdom | 1 | Completed | Aug 20, 2025 | 40 |
| NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 788 |
| NCT05952557Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 4, 2030 | 5,511 |
| NCT05774951Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Apr 20, 2027 | 4,300 |
| NCT05790304Lymphoma, Follicular · United States, Bulgaria, Slovakia | 1 | Completed | Feb 22, 2024 | 22 |
| NCT05551897Breast Neoplasms · United Kingdom | 1 | Completed | Dec 28, 2022 | 14 |
| NCT05438303Breast Neoplasms · United States | 1 | Completed | Dec 13, 2022 | 59 |
| NCT05364255Breast Neoplasms · United Kingdom | 1 | Completed | Jun 20, 2022 | 6 |
| NCT04964934Neoplasm Metastasis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jun 30, 2025 | 315 |
| NCT04818632Breast Neoplasms · China | 1 | Completed | Sep 7, 2023 | 28 |
| NCT04711252Neoplasm Metastasis · United States, Austria, Belgium and more | 3 | Active, not recruiting | Jun 26, 2026 | 1,371 |
| NCT04588298Breast Neoplasms · Georgia, Mexico, United Kingdom | 2 | Completed | Jun 19, 2023 | 135 |
| NCT04546347Breast Neoplasms · United Kingdom | 1 | Completed | Jan 7, 2021 | 32 |
| NCT04541433Breast Neoplasms · Japan | 1 | Completed | Jul 29, 2022 | 10 |
| NCT04214288Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Active, not recruiting | Aug 30, 2022 | 240 |
| NCT03616587Breast Neoplasms · United States, Spain, United Kingdom | 1 | Active, not recruiting | Sep 16, 2024 | 396 |
How it is read
Names in the registry
- “AZD9833”, 10 entries
- “Camizestrant”, 8 entries
- “AZD9833 with palbociclib”, 3 entries
- “AZD9833 with everolimus”, 3 entries
- “AZD9833 with abemaciclib”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 13 studies
- Neoplasm Metastasis, 4 studies
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.